Telestroke networks can be cost-effective for hospitals, good for patients

 

Augusta, Ga., USA (December 17, 2012) – Telestroke networks that enable the remote and rapid diagnosis and treatment of stroke can improve the bottom line of patients and hospitals, researchers report. A central hub hospital delivering rapid stroke diagnosis and treatment partnering with typically smaller spoke hospitals in need of those services means more patients recover better and the network – and hospitals – make money, according to a study in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes.

 

"We measure stroke treatment in reduced disability and improved function and we have clear evidence that patients who get timely intervention do best," said Dr. Jeffrey A. Switzer, stroke specialist at the Medical College of Georgia at Georgia Health Sciences University.

 

"If you are hospital administrator, you may like the idea conceptually but you have to be concerned about the risks of investing up front to do this. This is the first study to show that if it’s set up correctly, a telestroke network will more than pay for itself."

 

Switzer is corresponding author on the study using five years of patient and hospital data from telestroke networks at GHSU and the Mayo Clinic. Researchers plugged the data into a model designed to compare effectiveness and hospital costs with and without a telestroke network. The telestroke model has one hub and seven spokes, the average network size in the United States.

 

They found that annually with a network:

 

  • 45 more patients would receive the clot buster tPA, or tissue plasminogen activator, the only Food and Drug Administration-approved stroke drug
  • 20 more patients would receive endovascular therapy such as mechanically removing the clot from a blood vessel
  • Six more patients would be discharged to their home instead of a nursing home
  • The network made nearly $360,000, with each spoke hospital making more than $100,000

 

Major costs of telestroke networks include technology, technical support, transferring patients and paying physicians to take the extra call, said Switzer. "The question is whether it’s in the interest of hospitals to develop networks that set up these telestroke relationships."

 

The study suggests it is. It supports a model emerging across the nation, where large, hub hospitals such as GHS Medical Center pay equipment and other costs smaller hospitals incur using their network. In the vast majority of cases, patients are seen via the network by stroke specialists in Augusta, eligible patients are given tPA at the spoke hospital then transported to GHS Health System for follow-up care. A new iteration in recent years has larger, urban hospitals also utilizing the guaranteed acute stroke care but keeping most patients at their hospital afterward. The larger hospitals pay for their own telestroke equipment but also receive larger reimbursement from public and private insurance for their service, benefiting hospitals and patients, Switzer said. "Patients receive quality care and can stay closer to home."

 

A major driver behind these types of stroke-care extenders is a lack of stroke specialists. Georgia, for example, is nestled in the stroke belt and has less than 20 fellowship-trained stroke specialists to treat a population of 10 million. Each year only 50-60 stroke specialists complete training at centers across the nation such as MCG and GHS Health System.

 

The long-distance approach appears to work well: MCG researchers showed in a 2003 study published in the journal Stroke that stroke patients in rural communities could be assessed and treated via the wireless Internet program just as well as they could be in person.

 

While tPA has been FDA-approved for 16 years, still fewer than 5 percent of patients receive it, often because they don’t get a definitive stroke diagnosis within the three-hour time frame the drug should be given. Three separate clinical trials in the United States and Europe have shown it improves the likelihood of patients resuming normal or near-normal lives.

 

Dr. David Hess, stroke specialist and Chair of the MCG Department of Neurology, helped developed the Augusta system a dozen years ago, initially connecting with a small number of rural hospitals. Today, GHS Health System serves as the hub for 17 spokes. The biotech company, REACH Health, Inc., emerged about six years ago to help other hospitals and states develop similar networks.

 

 

The Circulation study was funded by Genetech, Inc., which produces and sells tPA in the U.S.

 


 

Georgia Health Sciences University, 17.12.2012 (tB).

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…